Literature DB >> 26080565

[Study on regulatory effect of Danshensu on lipid metabolism of hyperlipidemia rats].

Juan Chen, Jun Deng, Yu-yan Zhang, Jian-guo Li, Fei-yu Wu, Hai-tong Wan.   

Abstract

OBJECTIVE: To explore the effect of Danshensu on the lipid metabolism of hyperlipidemic rats.
METHOD: Sixty clean male SD rats were selected. Twelve of them were selected in the basic control group and fed with common foods, and the remaining rats were fed with the high-fat feeds. After the successful modeling, they were randomly divided into the high-fat control group and low dose (10 mg x kg(-1) x d(-1)), medium dose (20 mg x kg(-1) x d(-1)) and high dose (40 mg x kg(-1) x d(-1)) Danshensu (dissolved in saline) groups. Both of the two groups were abdominally injected with the same volume of normal saline once a day for consecutively 30 days. The serum TG, TC, HDL-C and liver ACC1, FAS, HMGR, CPT-I mRNA expressions were detected. RESULT AND
CONCLUSION: Danshensu could inhibit the LDL-C level, timely clear redundant cholesterol and effectively regulate the lipid metablism of hyperlipidemic rats by reducing the TC content, decrease the fatty acid by reducing the FAS mRNA expression, and reduce the synthesis levels of endogenous cholesterol by inhibit the HMGR mRNA expression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26080565

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  2 in total

1.  Erchen Decoction Ameliorates Lipid Metabolism by the Regulation of the Protein CAV-1 and the Receptors VLDLR, LDLR, ABCA1, and SRB1 in a High-Fat Diet Rat Model.

Authors:  Shanshan Ding; Jie Kang; Ling Tong; Yuchen Lin; Linghong Liao; Bizhen Gao
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-08       Impact factor: 2.629

Review 2.  The Effects of Salvia miltiorrhiza on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Wenjuan Shen; Bao Jin; Yaguang Han; Hongwei Wang; Huan Jiang; Linlin Zhu; Mei Han; Jiao Zhang; Yang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-15       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.